America's number of cancer drugs in development hits nearly 1,000; Medivation touts quality-of-life score for prostate cancer drug;

 @FierceBiotech: Look out, Roche: GlaxoSmithKline aces pivotal studies for pair of melanoma drugs. Story | Follow @FierceBiotech

 @JohnCFierce: Updated ASCO roundup story with regorafenib and Aveo study: More | Follow @JohnCFierce

 @RyanMFierce: My report on 5 next-gen software tools for biopharma R&D. Report | Follow @RyanMFierce

> Pharmaceutical Research and Manufacturers of America says that American biopharma groups have 981 cancer drugs and vaccines under development or regulatory review. Item

> CytRx ($CYTR) is presenting "favorable" results of its Phase Ib/II clinical trial for the tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors and primary soft tissue sarcomas. Release

> Medistem got the green light continue a clinical trial of a stem cell therapy for congestive heart failure after a safety check of 5 patients who had been treated in the study. Item

> Medivation ($MDVN) and Astellas Pharma touted data from a Phase III study of their experimental drug enzalutamide (formerly MDV3100) in measures of quality of life and time to first skeletal-related event in certain patients with prostate cancer. Release

Pharma News

 @FiercePharma: Some non-ASCO news: If Greece leaves euro, drug pricing across EU would get even worse, EFPIA says--Bloomberg. Article | Follow @FiercePharma

> J&J should split itself three ways, Goldman analyst says. More

> Study of Treanda shows great promise for Teva's drug. News

> ASCO: Data on J&J, Medivation meds spell trouble for Provenge. Story

Medical Devices News

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> SentreHEART pulls in $26M for surgical suture device. Article

> Device investment firm gets support from Medtronic, Abbott. News

> LabCorp grabs Medtox for $241M. More

> Boston Sci gets FDA nod for new stent sizes. Story

Biotech IT News

> Proteins computer-designed to block flu invasions. Story

> Accelrys software to support efforts in Texas to study rare cancers. Article

> NIH group to award up to $20B in IT contracts. More

> Dotmatics starts up mobile strategy with iPad app. News

And Finally… This year's $500,000 Lemelson-MIT prize went to Stanford University's Stephen Quake, a founder of Helicos BioSciences, whose biotech inventions could lead to non-invasive prenatal tests for Down syndrome and other genetic diseases. Report

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.